Introduction
Across Europe, breast cancer mortality had been rising until the mid-1980s. Since then, trends have changed, and falls started earlier in northern Europe, where breast cancer rates were originally higher (Levi et al., 2001 (Levi et al., , 2004a Botha et al., 2003; Tyczynski et al., 2004) . The largest falls (over 20%) were observed in the UK (Peto et al., 2000) , where however part of the decline was likely due to changes in coding and registration procedures introduced in the mid-1990s, which led to a rise in the proportion of deaths attributed to unspecified neoplasms (Rooney and Devis, 1996) . Since 1989 breast cancer mortality has also dropped by over 20% in US white (but not black) women, reflecting the contribution of early detection, increasing use of screening mammography and the introduction of adequate therapy (Lacey et al., 2002; Jemal et al., 2004) .
We have considered trends in breast cancer mortality in the 15 countries of the European Union (EU) and other European countries between 1988 and 1998: in the EU the fall was 26% at age 20-49, 9% at age 50-69 and 4% at age 70-79 (Levi et al., 2001 (Levi et al., , 2004a . In the mid-1990s, mortality was stable, or still somewhat upwards, in Poland, Hungary and a few other central and eastern European countries which entered the EU in May 2004. This may be related to the originally lower breast cancer rates in that area of the continent, but also to a delayed adoption of advancements in early diagnosis and treatment (Levi et al., 2004b) .
To further monitor recent trends in breast cancer mortality, we have updated trends in the EU, including 25 member states as of May 2004, and in separate European countries up to 2000, using joinpoint regression models (Kim et al., 2000) to define changes in trends over subsequent calendar periods.
Methods
Official death certification numbers for breast cancer up to 2000 for 38 European countries (including the Russian Federation, but excluding a few small countries such as Andorra and Liechtenstein) were derived from the World Health Organization (WHO) database as available on electronic support (World Health Organization, 2004) . Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, UK) . Data for Cyprus were not available. During the calendar period considered three different revisions of the International Classification of Diseases (ICD-8, ICD-9: 174; ICD-10: C50) were used (World Health Organization, 1967 , 1977 , 1992 . Classification of cancer deaths was recoded, for all calendar periods and countries, according to the Ninth Revision of the ICD (World Health Organization, 1977) .
Estimates of the resident population, generally based on official censuses, were obtained from the same WHO database (World Health Organization, 2004) . From the matrices of certified deaths and resident populations, we computed the age-specific rates for each 5-year age group and calendar year. We then obtained the age-standardized rates per 100 000 population at all ages and in three different age groups (i.e. 20-49, 50-69 and 70-79 years) using the direct method, and based on the world standard population (Doll and Smith, 1982) .
Joinpoint regression analysis was used to identify points where a significant change in the linear slope of the trend occurred (Kim et al., 2000) . In joinpoint analysis, the best fitting points (the 'joinpoints') are chosen where the slope changes significantly (increases or decreases). The analysis starts with the minimum number of joinpoints (e.g. 0 joinpoints, which is a straight line), and tests whether one or more joinpoints (up to 4) are significant and must be added to the model. In the final model each joinpoint (if any) informs of a significant change in the slope. The estimated annual percentage change (EAPC) is then computed for each of those trends by fitting a regression line to the natural logarithm of the rates using calendar year as a regressor variable (i.e. given y = a + bx, where y = ln(rate) and x = calendar year, the EAPC is estimated as 100*(e b -1)). The joinpoint analyses were performed using the 'Joinpoint' software from the Surveillance Research Program of the US National Cancer Institute (http://www-dccps.ims.nci.nih.gov/SRAB). Table 1 gives the age-standardized mortality rates from breast cancer at all ages and at age 20-49, 50-69, 70-79, in 1990, 1995 and 2000, in separate European countries, and in the EU as a whole, plus the corresponding changes in rates over the last calendar quinquennium. Most northern European countries, including Scandinavian countries and the UK, but also some central and southern European countries like Germany, Poland, the Czech Republic, Austria, Switzerland, Italy and Spain showed appreciable falls in rates, namely between 8 and 19% in the last 5 calendar years. The declines were larger in the younger age groups, approaching 20% in several countries below age 50. More importantly, most major European countries showed falls in breast cancer rates below age 70. The falls were smaller in France, Greece or Portugal, and most eastern European countries. In the Russian Federation, overall breast cancer mortality increased from 16.1 to 17.3/100 000 (+ 7.5% over the last 5 calendar years). In the EU as a whole, breast cancer mortality rates declined from 21.3/100 000 women in 1990 to 18.9/100 000 in 2000. Table 2 and Fig. 1 give the results of the joinpoint analysis for breast cancer mortality trends in the EU between 1970 and 2000. At all ages, breast cancer rates rose by 0.7% per year between 1970 and 1989, declined by 0.8% per year between 1989 and 1995, and by 2.1% per year thereafter. At age 20-49, the rise was 0.2% until 1989, the fall was -1.3% between 1989 and 1994, and -2.9% thereafter. At age 50-69, the rise was 0.8% until 1988, the fall was -0.6% between 1988 and 1995, and -2.2% thereafter. At age 70-79 the joinpoint trend was more complex, with a rise by 0. 7% between 1970 and 1980, by 1.8% between 1980 and 1986, by 0.3 between 1986 and 1993 , and a decline by -1.3% thereafter.
Results

Discussion
The main finding from the present updated analysis of breast cancer mortality trends in Europe is the documentation and quantification of a continuing fall in rates, which has been larger over the last few years in the EU as a whole, and consequently in most European countries. Overall in the EU, such a fall approached 10% between 1995 and 2000, corresponding to a decline of -2.1% per year. The fall in the US between 1992 and 2001 has been even larger (i.e. -2.4% per year; Jemal et al., 2004) . The use of joinpoint analysis allowed a detailed description of changes in trends in breast cancer mortality over the last decades, showing that the falls have been larger at younger age, while having started only around the mid-1990s in women above age 70 (Tyczynski et al., 2004) .
There are potential problems of reliability and validity of death certification for breast cancer, which may vary across countries, calendar periods and age groups (Percy et al., 1981; Boyle, 1989) . However, breast death certification is sufficiently reliable to permit meaningful inference on trends for most European countries, particularly those from western Europe, as well as for major central and eastern European countries, chiefly under the age of 65 years. Some under-recording of cancer deaths was reported for the Russian Federation in the late 1980s and 1990s, due to a fall in precision of coding of causes of death. This was, however, mainly restricted to the elderly living in rural areas (Shkolnikov et al., 1999) , and should therefore not have materially influenced truncated rates. Greater caution is required for a few other countries, such as Kyrgyzstan and Uzbekistan, whose rates were relatively low, and a few other new national entities, for which no long-term trend was available. In these countries, breast cancer diagnosis and certification has been influenced by changed availability of diagnostic techniques and the accuracy of death certification, reflecting variable data reliability, and different criteria and attitudes towards death Breast cancer mortality in Europe Levi et al. 499 certification. Changes in diagnosis and certification are unlikely, however, to explain the recent fall in mortality rates across most European countries.
There are a few outliers to this generally favourable pattern of breast cancer rates in Europe, including the Russian Federation and a few eastern European countries (i.e. Bulgaria, Croatia and Romania), whose rates, however, started from low values (La Vecchia, 1994) .
It is unlikely that such changes in rates are due to substantial changes in the incidence of the disease, since major recognized risk factors for breast cancer, including nulliparity or low parity, later age at first birth, hormone replacement therapy and overweight in post-menopause (Tavani et al., 1997; Pagano et al., 1997) 1996) . Other modifiable risk factors, such as selected aspects of diet or physical activity (Henderson et al., 1996; Mezzetti et al., 1998; Boyle et al., 2004) , are also unlikely to have induced such substantial changes as those required to cause such a large decline in breast cancer mortality. Thus, the incidence of breast cancer in Europe has, if anything, increased in Europe over the last two decades, following the introduction of screening (Botha et al., 2003) . 1965 1970 1975 1980 1985 1990 1995 2000 2005 Calendar year Mortality rate per 100000 (b) 0 5 10 15 1965 1970 1975 1980 1985 1990 1995 2000 2005 Calendar 1965 1970 1975 1980 1985 1990 1995 2000 2005 Calendar year Mortality rate per 1 00 000 1965 1970 1975 1980 1985 1990 1995 2000 2005 Calendar year Mortality rate per 1 00 000 Joinpoint analysis of trends in age-standardized (world population) mortality rates (per 100 000 women) from breast cancer in the European Union Consequently, the fall in breast cancer mortality observed in most European countries over the last decade has to be attributed essentially to earlier detection and improved treatment. Earlier diagnosis probably includes both organized mammography screening programmes, which cover a number of northern European countries, and perhaps also non-organized and opportunistic mammography which is widespread across (western) Europe (International Agency for Research on Cancer, 2002; Fracheboud et al., 2004) . In several countries with screening programmes, decreases in mortality started before organized screening was introduced. Improved treatment includes the wider adoption of adjuvant hormonal and chemotherapy, and the consequent increased survival, and perhaps also some advancement in radiotherapy and surgery (Early Breast Cancer Trialists' Group, 1998a,b; Garattini and La Vecchia, 2001; Fyles et al., 2004; Fisher et al., 2004) .
In conclusion, the present analysis of breast cancer in Europe shows that similar mortality rates over recent calendar years have been reached by countries (mainly from northern Europe) where the mortality has been decreasing for more than a decade, and in those countries (mainly eastern and Mediterranean countries) which have experienced a levelling-off and incipient decrease, or the few ones whose rates have still been rising. Overall, these patterns reflect converging trends in breast cancer rates across Europe, which can be related to the more uniform reproductive and lifestyle habits in various areas of the continent over the last few decades (La Vecchia et al., 2003) . The definite reasons for the different trends in various countries remain at least in part unclear. Nonetheless, if recent trends are maintained, breast cancer mortality is likely to further appreciably decline in the EU in the current decade (Quinn et al., 2003) .
